VivoSeq
Other

Immune Response

0

Pipeline Programs↗

34

Active Trials↗

16

Companies Involved↗

Immune Response is an early-stage landscape with 0 programs across 16 companies. The most active players are GSK, Novartis, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalAstellas logo

Astellas

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

326

clinical trials

Completed254 · 78%
Recruiting18 · 6%
Unknown status17 · 5%
Active, not recruiting13 · 4%
Terminated12 · 4%
Withdrawn9 · 3%
Other3 · 1%

Clinical Trials

Trial Activity

326 trials

Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Recruiting·CCanadian Immunization Research Network·Phase 4·NCT07156084·300 enrolled
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
Recruiting·IInstitut Pasteur·N/A·NCT05897879·210 enrolled
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
Recruiting·RRenJi Hospital·N/A·NCT04871932·50 enrolled
Bone Marrow and Peripheral Blood Immune Responses Study
Recruiting·EEmory University·Phase 4·NCT05616546·90 enrolled
Immune Responses in Health Care Personnel
Recruiting·FFinnish Institute for Health and Welfare·N/A·NCT03323112·150 enrolled
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Recruiting·—·Phase 3·NCT05726786·232 enrolled
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Recruiting·FFundación GECP·N/A·NCT06634199·50 enrolled
Characterizing the Human Airway Immune Response to FluMist Vaccination
Recruiting·WWashington University School of Medicine·Phase 4·NCT07177417·30 enrolled
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
Recruiting·GSK logoGSK·Phase 4·NCT06113198·50 enrolled
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Recruiting·BioMarin Pharmaceutical logoBioMarin Pharmaceutical·N/A·NCT06305234·200 enrolled
Antibiotics and Vaccine Immune Responses Study
Recruiting·SSouth Australian Health and Medical Research Institute·Phase 4·NCT06148025·348 enrolled
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06624839·120 enrolled
A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
Recruiting·GSK logoGSK·Phase 2·NCT06213506·516 enrolled
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT05672927·618 enrolled
Description of the Immune Response to Yellow Fever Vaccination
Recruiting·IInstitut Pasteur·N/A·NCT06718127·38 enrolled
Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)